Literature DB >> 15947013

Epidemiology of juvenile-onset inflammatory bowel disease in central Saudi Arabia.

Mohammad Issa El Mouzan, Asaad Mohammad Abdullah, Mohammad Talal Al Habbal.   

Abstract

There is limited information about inflammatory bowel disease in Arab children. Hence, the objective of this study was to report on the epidemiology of this condition in our community. Medical records were analysed for all children below 18 years of age diagnosed with inflammatory bowel disease (IBD) and followed up in our institution over a period of 10 years. From 1993 to 2002, 50 consecutive children were diagnosed to have IBD. This gives an estimated incidence of 0.5 cases/100 000/year and a prevalence of 5 cases/100 000 populations for the region of Riyadh, Saudi Arabia. Most of the children (90 per cent) were Saudi nationals and the female to male ratio was 1 : 0.6. The age range was between 5 and 18 years with 16 per cent of the cases diagnosed in children below 12 years of age. Chronic ulcerative colitis was the commonest form accounting for 48 per cent, followed by Crohn's disease and indeterminate colitis in 38 per cent and 16 per cent of the children, respectively. The best agreement between colonoscopic and histopathologic findings (89 per cent) was in children with ulcerative colitis followed by normal findings and Crohn's disease in 63 per cent and 35 per cent of the cases, respectively. It was concluded that the incidence and prevalence of IBD in this report are lower than in any other population. Nevertheless, comparison with older data suggests that the incidence is increasing.

Entities:  

Mesh:

Year:  2005        PMID: 15947013     DOI: 10.1093/tropej/fmi039

Source DB:  PubMed          Journal:  J Trop Pediatr        ISSN: 0142-6338            Impact factor:   1.165


  24 in total

Review 1.  Recent trends in the epidemiology of inflammatory bowel diseases: up or down?

Authors:  Peter-Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

Review 2.  Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?

Authors:  A A van Bodegraven; Chris J J Mulder
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

3.  Expression of CD200R1 and its Ligand CD200 on T-helper Lymphocytes of Pediatric Patients with Ulcerative Colitis and Crohn's Disease.

Authors:  Mohamed F Elshal; Alia M Aldahlawi; Omar I Saadah; J Philip Mccoy
Journal:  Clin Lab       Date:  2016-08-01       Impact factor: 1.138

4.  Clinical epidemiology of ulcerative colitis in Arabs based on the Montréal classification.

Authors:  Othman R Alharbi; Nahla A Azzam; Ahmed S Almalki; Majid A Almadi; Khalid A Alswat; Nazia Sadaf; Abdulrahman M Aljebreen
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

5.  Inflammatory bowel disease register: Steps towards Crohn's & colitis foundation of Saudi Arabia (CCFSA).

Authors:  Ibrahim Masoodi; Khalid Alsayari; Jamal Albishri
Journal:  Int J Health Sci (Qassim)       Date:  2012-06

6.  Crohn's disease in a Saudi outpatient population: is it still rare?

Authors:  Mohammad A Al-Mofarreh; Ibrahim A Al Mofleh; Ibrahim N Al-Teimi; Abdulrahman M Al-Jebreen
Journal:  Saudi J Gastroenterol       Date:  2009-04       Impact factor: 2.485

7.  Tuberculosis, onychomycosis and immune deficiency in complicated Crohn's disease.

Authors:  Rayan Hejazi; Mohammed Hasosah
Journal:  BMJ Case Rep       Date:  2019-08-04

8.  Childhood Inflammatory Bowel Disease in Libya: Epidemiological and Clinical features.

Authors:  Ai Ahmaida; Sa Al-Shaikhi
Journal:  Libyan J Med       Date:  2009-06-01       Impact factor: 1.657

9.  Pediatric Crohn's Disease in Bahrain.

Authors:  Hasan M Isa; Afaf M Mohamed; Halima E Al-Jowder; Khadija A Matrook; Haya H Althawadi
Journal:  Oman Med J       Date:  2018-07

10.  Emerging inflammatory bowel disease in saudi outpatients: a report of 693 cases.

Authors:  Mohammad A Al-Mofarreh; Ibrahim A Al-Mofleh
Journal:  Saudi J Gastroenterol       Date:  2013 Jan-Feb       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.